- Home
- SNTI vs MGRM Comparison
SNTI vs MGRM Comparison
Compare SNTI & MGRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- MGRM
- Stock Information
- Founded
- SNTI 2016
- MGRM 2016
- Country
- SNTI United States
- MGRM United States
- Employees
- SNTI N/A
- MGRM N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- MGRM Medical/Dental Instruments
- Sector
- SNTI Health Care
- MGRM Health Care
- Exchange
- SNTI Nasdaq
- MGRM Nasdaq
- Market Cap
- SNTI 85.3M
- MGRM 79.9M
- IPO Year
- SNTI N/A
- MGRM N/A
- Fundamental
- Price
- SNTI $3.35
- MGRM $2.68
- Analyst Decision
- SNTI Strong Buy
- MGRM Strong Buy
- Analyst Count
- SNTI 1
- MGRM 1
- Target Price
- SNTI $12.00
- MGRM $5.40
- AVG Volume (30 Days)
- SNTI 226.4K
- MGRM 51.5K
- Earning Date
- SNTI 05-06-2025
- MGRM 05-14-2025
- Dividend Yield
- SNTI N/A
- MGRM N/A
- EPS Growth
- SNTI N/A
- MGRM N/A
- EPS
- SNTI N/A
- MGRM N/A
- Revenue
- SNTI N/A
- MGRM N/A
- Revenue This Year
- SNTI N/A
- MGRM N/A
- Revenue Next Year
- SNTI N/A
- MGRM N/A
- P/E Ratio
- SNTI N/A
- MGRM N/A
- Revenue Growth
- SNTI N/A
- MGRM N/A
- 52 Week Low
- SNTI $1.52
- MGRM $1.84
- 52 Week High
- SNTI $16.94
- MGRM $4.21
- Technical
- Relative Strength Index (RSI)
- SNTI 45.79
- MGRM 49.20
- Support Level
- SNTI $3.10
- MGRM $2.62
- Resistance Level
- SNTI $3.50
- MGRM $3.14
- Average True Range (ATR)
- SNTI 0.39
- MGRM 0.19
- MACD
- SNTI -0.07
- MGRM -0.02
- Stochastic Oscillator
- SNTI 20.36
- MGRM 37.48
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About MGRM Monogram Orthopaedics Inc.
Monogram Technologies Inc develops a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. The company has a robot prototype that can autonomously execute optimized paths for high-precision insertion of implants in synthetic bone specimens. Monogram also intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures.